Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aclaris Therapeutics, Inc. - Common Stock (NQ:ACRS)

2.060 +0.070 (+3.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Aclaris Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus
U.S. stock futures rose on Wednesday after ending lower on Tuesday. Futures of major benchmark indices were slightly higher. 
Via Benzinga
Aclaris Therapeutics Stock Spikes In After‑Hours Session Following Major Announcement
Aclaris Therapeutics Inc (NASDAQ: ACRS) surgged 21.94% in after-hours trading on Tuesday after positive top-line results from its open-label Phase 2a trial. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
What's going on in today's after hours session
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
Aclaris Therapeutics: Q4 Earnings Insights
 
Via Benzinga
The Analyst Landscape: 4 Takes On Aclaris Therapeutics
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
This Arista Networks Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Aclaris Stock Rises As Analyst Projects Billions In Sales For New Therapy
HC Wainwright upgraded Aclaris Therapeutics (ACRS) to Buy with a $20 price target. Aclaris gains after licensing agreement with Biosion for potential best-in-class therapies for atopic dermatitis and... 
Via Benzinga
Santa Rally, January Effect, And Top Stock Picks
Explore December 23's top pre-market picks, macro insights, and Santa Rally opportunities with StoryTrading's 4-pillar strategy. Join the community for exclusive trade ideas! 
Via Talk Markets
Topics Stocks / Equities
This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday
 
Via Benzinga
Level Up Your Trading: Inside The 4-Pillar Strategy Behind Triple-Digit Returns
Explore market insights and top picks with our 4-pillar strategy. 
Via Talk Markets
Topics Stocks / Equities
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Aclaris Stock Soars As Analysts See Fresh Momentum After Strategic Review And Encouraging Promising Pipeline Developments
Aclaris secures global rights to Biosion's BSI-045B, advancing trials for atopic dermatitis, asthma, and more. Stock surges on promising updates. 
Via Benzinga
War, Gold, And Opportunity: Uncovering Today’s Market Moves
Geopolitical tensions drive market moves as we analyze top picks. 
Via Talk Markets
This BioNTech Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Aclaris Therapeutics And 3 Other Stocks Under $2 Insiders Are Buying
 
Via Benzinga
Aclaris Therapeutics And 1 Other Stock Under $5 Insiders Are Buying
 
Via Benzinga
$1.8M Bet On This Health Care Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
ACRS Stock Earnings: Aclaris Therapeutics Beats EPS, Beats Revenue for Q1 2024
ACRS stock results show that Aclaris Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed lower by over 400 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades
HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape. 
Via Benzinga
Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of CommScope Holding Company, Inc. (NASDAQ: COMM) fell sharply during Monday’s session. B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the... 
Via Benzinga
Why Coherus BioSciences Shares Are Trading Higher By 22%; Here Are 20 Stocks Moving Premarket
Shares of Coherus BioSciences, Inc. (NASDAQ: CHRS) shares rose sharply in today’s pre-market trading after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Why Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?
Aclaris Therapeutics leadership changes and strategic review. Preliminary unaudited data as of Dec 31, 2023, reveals approximately $182M in cash, cash equivalents, and marketable securities. Aclaris... 
Via Benzinga
Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations
Wednesday, Aclaris Therapeutics Inc (NASDAQ: ACRS) released topline results from its Phase 2b study of ATI-1777, an investigational topical "soft" JAK 1/3 inhibitor, in patients with mild to  
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.